财报解读丨亏损收窄26.9%,研发烧钱19.5亿,百济神州的盈利困局如何破?

美股研究社
28 Mar

来源 | 美股研究社整理近年来,全球肿瘤免疫治疗市场掀起PD-1/PD-L1抑制剂研发浪潮,中国药企凭借成本优势与临床效率强势崛起。然而,随着赛道拥挤度攀升,行业洗牌加速——恒瑞、信达、百济神州等头部企业既要应对国内价格战,又需突破海外专利壁垒。百济神州2024年财报显示,其全年营收同比增长55%至38.1亿美元,核心产品泽布替尼(百悦泽)全球收入突破26亿美元,同比激增104.9%,成为首个跻身...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10